Tag: Cancer: Lung
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is Low
Increase in UTD-LCS prevalence seen with age and number of comorbidities; relatively lower levels seen in Southern states
Lung Cancer Screening Increases Earlier-Stage Diagnoses, Improves Survival
Uptake of lung cancer screening was low, but overall and lung cancer-specific survival improved with screening
ASCO: Ivonescimab Improves Progression-Free Survival in EGFR+ Lung Cancer
PFS benefit seen in most subgroups, including those whose disease progressed while receiving third-generation EGFR-TKIs
ASCO: Osimertinib Improves Progression-Free Survival in EGFR-Mutated Lung Cancer
Significantly longer progression-free survival, but not overall survival, seen for osimertinib in unresectable EGFR-mutation NSCLC
Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer
Drug approved for patients with ALK-positive, early-stage cancer who undergo surgery to remove their tumor
Adjuvant Alectinib Improves Disease-Free Survival in Lung Cancer
Findings seen among patients with resected ALK-positive non-small cell lung cancer
Eligibility for Lung Cancer Screening Up With 2021 USPSTF Recommendations
Of those newly eligible under 2021 criteria, 2,063,840 were aged 50 to 54 years and 4,020,879 had 20 to 29-pack-year smoking history
EPA Issues Final Rule Banning Asbestos
Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
Significant benefit seen for neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab
Pegargiminase + Chemo Increases Survival Rate in Nonepithelioid Pleural Mesothelioma
Improved median overall survival and progression-free survival seen for pegargiminase-based chemotherapy
